Optibiotix Health (OPTI)


Latest News

Exercise of Warrant and Issue of Equity

RNS Number: 8753W OptiBiotix Health PLC 17 November 2017 OptiBiotix Health plc ("OptiBiotix" or the "Company") Exercise of warrant and issue of equity OptiB i ot i x H ealth p l c (A I M: O P TI), a li f e sc i ences bu s i n ess d e ve l o p i n g c o m p o u n d s to tack l e o b esi t y, h i g h chole s te r ol, d ia b ete s has received a notification for the exercise of warr...

SlimBiome? commercial & product development update

RNS Number: 8284V OptiBiotix Health PLC 08 November 2017 OptiBiotix Health plc ("OptiBiotix" or the "Company") SlimBiome commercial and product development update OptiB i ot i x H ealth p l c (A I M: O P TI), a li f e sc i ences bu s i n ess d e ve l o p i n g c o m p o u n d s to tack l e o b esi t y, h i g h chole s te r ol, d ia b ete s and skin care provides the follow...

Manufacturing, supply & profit sharing agreement

RNS Number: 1441V OptiBiotix Health PLC 01 November 2017 OptiBiotix Health plc ("OptiBiotix" or the "Company") Manufacturing, supply and profit sharing agreement with Knighton Foods OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a man...

OptiBiotix to present research

OptiBiotix Health said it will present research data on its microbiome modulators at the MicroBiome R&D and Business C...

All News

17-11-17Exercise of Warrant and Issue of EquityRNS
08-11-17SlimBiome? commercial & product development updateRNS
01-11-17Manufacturing, supply & profit sharing agreementRNS
26-10-17OptiBiotix to present researchStockMarketWire
26-10-17Presentation of researchRNS
24-10-17OptiBiotix signs product supply agreementStockMarketWire
24-10-17LPLDL? supply agreement with GalenicumRNS
04-10-17Successful launch of products at Supply Side WestRNS
19-09-17Technical, regulatory & commercial updateRNS
13-09-17OptiBiotix Health signs MoU with Bened BiomedicalStockMarketWire
13-09-17Strategic partnership with Bened BiomedicalRNS
11-09-17Holding(s) in CompanyRNS
07-09-17Invited to present at Expoquimia in BarcelonaRNS
06-09-17Investor eveningRNS
05-09-17Manufacturing Agreement with Tata ChemicalsRNS
01-09-17Exercise of Options and Issue of EquityRNS
30-08-17OptiBiotix loss widens on higher expensesStockMarketWire
30-08-17Half-year ReportRNS
24-08-17OptiBiotix Health to launch LPLDL at Supply Side West in USStockMarketWire
24-08-17US product launch of LPLDL? at trade showRNS
22-08-17OptiBiotix seals new deal with SaccoStockMarketWire
22-08-17Global manufacturing & supply agreement with SaccoRNS
31-07-17Total Voting RightsRNS
26-07-17Market launch for LPLDL? capsules in GermanyRNS
17-07-17OptiBiotix Health seals deal with Pharmabiota NZStockMarketWire
17-07-17Supply agreement with Pharmabiota LtdRNS
11-07-17SweetBiotix? development: Results of taste studyRNS
06-07-17Grant of OptionsRNS
15-06-17All resolutions passed at AGM of OptiBiotixStockMarketWire
15-06-17Result of AGMRNS
15-06-17OptiBiotix in supply agreement with HLH BiopharmaStockMarketWire
15-06-17Supply agreement with HLH Biopharma GmbHRNS
31-05-17Holding(s) in CompanyRNS
16-05-17OptiBiotix Health launches LPLDL,SlimBiome productsStockMarketWire
16-05-17Successful launch of LPLDL and SlimBiome productsRNS
09-05-17OptiBiotix notes non-exclusive European licence dealStockMarketWire
09-05-17LPLDL? Non-Exclusive European License AgreementRNS
03-05-17Presentation of abstract at conferenceRNS
25-04-17Optibiotix discusses 'critical' couple of yearsInteractive Investor
25-04-17Optibiotix Health notes first German sales of LPLDLStockMarketWire

RSS feeds

  • Editorial news feed for LSE:OPTI Editorial
  • Regulatory news feed for LSE:OPTI Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account